2-deoxy-2-[18F]fluoro-D-glucose (FDG)

BIOLOGICAL3 trials

Sponsors

Genentech, Inc., Abramson Cancer Center at Penn Medicine, H. Lee Moffitt Cancer Center and Research Institute

Conditions

Breast CancerBreast Cancer, FemaleBreast Cancer, MaleBreast NeoplasmsNon-Hodgkin LymphomaNon-Small Cell Lung Cancer

Early Phase 1

PET-CT Imaging Using FDG-labeled Human Erythrocytes in Breast Cancer Patient

WithdrawnNCT03295695

H. Lee Moffitt Cancer Center and Research InstituteBreast Cancer, Breast Cancer, Female, Breast Cancer, Male +1

Start: 2020-12-31End: 2022-12-31Updated: 2020-12-04

Phase 1

A Study of Changes in FDG- and FLT-PET Imaging in Patients With Non-Small Cell Lung Cancer Following Treatment With Erlotinib

CompletedNCT00453362

Genentech, Inc.Non-Small Cell Lung Cancer

Start: 2006-12-31End: 2010-04-23Updated: 2017-03-31

Unknown Phase

Early FDG PET/CT Imaging as a Measure of Response in Patients With Non-Hodgkin Lymphoma on Lenalidomide

TerminatedNCT03065790

Abramson Cancer Center at Penn MedicineNon-Hodgkin Lymphoma

Start: 2017-02-06End: 2021-04-28Updated: 2021-06-04